Harkins Keegan A, Haschke Mary, Do Diana V
Truhlsen Eye Institute, University of Nebraska Medical Center, 3902 Leavenworth St, Omaha, NE 68105, USA.
Immunotherapy. 2016 May;8(5):503-10. doi: 10.2217/imt.16.5. Epub 2016 Feb 24.
Diabetic macular edema (DME) is an accumulation of fluid in the central retina, secondary to vascular-leakage from diabetic vascular damage. DME and other ophthalmic sequela of diabetes are the leading cause of blindness in 20 to 74-year-olds. The development of VEGF-inhibitors (anti-VEGF) has revolutionized DME treatment improving the clinician's ability to remove excess fluid from the macula, improving visual-acuity. Aflibercept is an anti-VEGF agent made of a recombinant fusion protein (consisting of VEGF receptors 1 and 2 extracellular domains) fused with the Fc-portion of human-IgG1, which binds both VEGF isoforms A and B, and placental growth factor. Phase III clinical trials and published scientific studies have demonstrated the efficacy of intravitreal aflibercept injection in the treatment of DME.
糖尿病性黄斑水肿（DME）是中央视网膜的液体蓄积，继发于糖尿病性血管损伤导致的血管渗漏。DME和糖尿病的其他眼部后遗症是20至74岁人群失明的主要原因。血管内皮生长因子抑制剂（抗VEGF）的发展彻底改变了DME的治疗方式，提高了临床医生从黄斑区清除多余液体的能力，改善了视力。阿柏西普是一种抗VEGF药物，由重组融合蛋白（由血管内皮生长因子受体1和2的细胞外结构域组成）与人IgG1的Fc部分融合而成，它能结合血管内皮生长因子A和B两种亚型以及胎盘生长因子。III期临床试验和已发表的科学研究证明了玻璃体内注射阿柏西普治疗DME的疗效。
